Niraparib Tosylate APIs are a part of Loncom Pharma’s oncology line-up, serving as maintenance treatment for ovarian cancer. As a PARP inhibitor, it plays a crucial role in exploiting cancer cell DNA repair pathway deficiencies, thus preventing cancer progression.
Shandong Loncom Pharmaceutical Co., Ltd is founded in 2012, located in Qihe Economic Development Zone, Shandong Province, with a registered capital of 60 million yuan.
